Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Baylor College of Medicine
Mayo Clinic
Corvus Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
Seagen Inc.
Bristol-Myers Squibb
Medical College of Wisconsin
Novartis
National Institutes of Health Clinical Center (CC)
Pfizer
Fondazione Italiana Linfomi - ETS
Children's Cancer Group, China
Autolus Limited
Hoffmann-La Roche
Fred Hutchinson Cancer Center
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
SymBio Pharmaceuticals
City of Hope Medical Center
Seagen Inc.
M.D. Anderson Cancer Center
Mayo Clinic
Princess Maxima Center for Pediatric Oncology
Cancer Research UK
Turning Point Therapeutics, Inc.
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
New York Medical College
M.D. Anderson Cancer Center
Takeda
Universität des Saarlandes
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
City of Hope Medical Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Children's Cancer Group, China
Ohio State University Comprehensive Cancer Center
Boehringer Ingelheim
Eastern Cooperative Oncology Group
BeiGene
University of Nebraska
Children's Oncology Group
Columbia University